Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Pan-India diagnostic testing company focused on high-volume, low-cost preventive and wellness biochemistry testing, operating a hub-and-spoke model with a central processing laboratory in Navi Mumbai and regional labs. Known for its Aarogyam wellness test panels; also operates nuclear imaging (PET-CT) through its NHL subsidiary. Majority-owned by API Holdings (PharmEasy) after the 2021 acquisition from founder A. Velumani; revenue is driven by B2B franchise/aggregator volumes and wellness packages.
One of India's largest diagnostic chains by test volumes, with a distinctly B2B- and wellness-weighted model versus pathology peers.
Thyrocare Technologies Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Thyrocare Technologies Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
Per-share figures are not restated. Shares outstanding changed from 5.30 crore to 15.92 crore in FY26, consistent with a bonus issue or stock split. Each year's EPS and book value below are as that year was filed, on that year's share count — so the per-share line falls across FY26 even where profit did not. Compare the absolute figures (EBITDA, free cash flow, total debt) and the margins across that boundary, not the per-share ones.
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 10.27 | 17.13 | 13.42 |
| Book value / share (₹) | 36.82 | 103.24 | 99.65 |
| Return on equity | 27.8% | 16.7% | 13.4% |
| Return on capital employed | 31.9% | 23.7% | 16.3% |
| Operating margin | 24.5% | 19.7% | 15.8% |
| Net margin | 19.6% | 13.2% | 12.2% |
| EBITDA | ₹262 Cr | ₹190 Cr | ₹137 Cr |
| Free cash flow | ₹192 Cr | ₹146 Cr | ₹106 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹22 Cr |
| Debt to equity | 0.00 | 0.00 | 0.04 |
| Interest coverage | 72.7 | 44.3 | 21.5 |
| Current ratio | 3.39 | 2.77 | 3.08 |
| Shares outstanding | 15,91,70,000 | 5,29,90,000 | 5,29,50,000 |
Open the full income statement, balance sheet and cash flow for THYROCARE →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.